CardioFocus today announced that it signed a licensing and distribution agreement with China Grand Pharmaceutical to seek regulatory approvals for the HeartLight X3 catheter ablation technology in China.
Marlborough, Mass.-based CardioFocus designed the HeartLight X3 system for controlled and consistent pulmonary vein isolation, which is the primary treatment for atrial fibrillation (AFib).
Get the full story on our sister site, Medical Tubing + Extrusion.